# PREDICTIVE DRUG TESTING IN ORGANOID MODELS

> **NIH NIH N01** · LEIDOS BIOMEDICAL RESEARCH, INC. · 2024 · $7,879,910

## Abstract

High-throughput screening (HTS) of approved and investigational agents in organoid models established from patient-derived tumor tissues. These studies will assist NCI in identifying drug responsive tumors and enable the active investigation of the underlying mechanism(s) of action, predictive biomarkers of response and/or resistance to agents, and the effects of genetic alterations on drug efficacy.

## Key facts

- **NIH application ID:** 11195485
- **Project number:** 75N91019D00024-P00002-759102000032-1
- **Recipient organization:** LEIDOS BIOMEDICAL RESEARCH, INC.
- **Principal Investigator:** ETHAN DMITROVSKY
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $7,879,910
- **Award type:** —
- **Project period:** 2020-09-25 → 2029-09-18

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11195485

## Citation

> US National Institutes of Health, RePORTER application 11195485, PREDICTIVE DRUG TESTING IN ORGANOID MODELS (75N91019D00024-P00002-759102000032-1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/11195485. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*